Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: Results of the austrian multicenter phase II study (Q57636866)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Michael A Fridrik

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

J Thaler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

W Hilbe

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

U Apfelbeck

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

W Linkesch

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

H Seewann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J Pont

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

M Bernhart

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

M Stöger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

H Niessner

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

K Abbrederis

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

D Geissler

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

H Hausmaninger

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

W Lin

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

H Ludwig

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A Lang

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

C Duba

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

T Fluckinger

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

R Greil

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

K Grünewald

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

G Konwalinka

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

D Niederwieser

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

75-80

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Chronic myelogenous leukemia--new concepts (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

New chromosome techniques in the study of human neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900084-7

7 January 2021

10.1016/S0145-2126(96)00084-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9029189%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference